Throw the predictions out of the window. Any thoughts that the number of biotech initial public offerings (IPO) would slow down anytime soon will surely be dispelled with the successful completion of five offerings. Cara Therapeutics Inc., Trevena Inc. and Ultragenyx Pharmaceutical Inc. have followed Dicerna Pharmaceuticals Inc. and Celladon Corp., which priced their IPOs Thursday.